← All candidates
17 insider buys in the last year — $1.64M in all.
85 filings on record.
TRDAEntrada Therapeutics, Inc.
NasdaqGM · Healthcare · $269.05M
$6.88
-2.41% · Sep 15
17 insider buys in the last year — $1.64M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 17 buys● 36 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$269.05M
Float
20.1M
52% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
57.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Baker Bros. Advisors LP
Bought $625.3K on Nov 12 — 80,881 sh @ $7.73, held indirect, 1.7% of their stake.
5 of 5 positions beat the S&P
Director
Zeiher Bernhardt G
Bought $29.3K on May 20 — 5,000 sh @ $5.86, held indirect, 100% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
80 more transactions on Pro →Context
Wall St
$18.75 avg target
+172.5% vs today · 4 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.95 act+$0.07
Q4 '25−$0.94 act+$0.22
Q3 '25−$1.06 act−$0.10
Q2 '25−$1.04 act−$0.18
Coverage
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety ProfileMarketBeat · 05-09Entrada’s stock drops as DMD drug’s efficacy falls shortClinical Trials Arena · 05-08Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue EstimatesZacks · 05-07Entrada shares dive as Duchenne results disappointBioPharma Dive · 05-07
The file stays open
85 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice